Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hematodermic CD4/CD56 neoplasm].

Tony Petrella1, Janine Wechsler, Philippe Courville

  • 1Centre de Pathologie, 33 rue Nicolas Bornier, BP189, 21005, Dijon Cedex, France. tony.petrella@centre-de-pathologie.fr

Annales De Pathologie
|October 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma.

Translational lung cancer research·2026
Same author

Main histopathological difficulties in diagnosing atypical melanocytic proliferations using MPATH-Dx V2: impact on patient management based on 6006 files referred for second opinions.

Pathology·2026
Same author

Cutaneous leukocytoclastic vasculitis leading to extensive digital necrosis as the only COVID-19 clinical manifestation.

Vascular diseases (Paris, France)·2026
Same author

AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Uncovering regulatory B-cell features associated with regulatory T-cell expansion and global T-cell exhaustion in Waldenström macroglobulinemia <i>Myd88</i> <sup><i>L252P</i></sup> -like lymphoplasmacytic lymphomas.

HemaSphere·2025
Same author

CLL-like stereotyped BCRs are equally produced in young and old healthy adults, share features of public clonotypes and may be stuck at a pre-germinal centre stage.

British journal of haematology·2025

Hematodermic CD4/CD56 neoplasm, also known as blastic NK-cell lymphoma, is a rare skin cancer with poor prognosis. Its exact cell origin remains uncertain, despite research suggesting a plasmacytoid dendritic cell link.

Area of Science:

  • Hematology
  • Oncology
  • Dermatology

Background:

  • Hematodermic CD4/CD56 neoplasm is a recently identified malignancy.
  • First described in 1994, it was initially named by the French Study Group on Cutaneous Lymphomas in 1999.
  • Previously classified as blastic NK-cell lymphoma, its precise lineage and etiology are still under investigation.

Purpose of the Study:

  • To conceptualize the entity by its main clinical and phenotypical characteristics.
  • To explore the potential origin of the tumor cells.
  • To highlight the diagnostic criteria and poor prognosis of this neoplasm.

Main Methods:

  • Analysis of clinical, pathological, and phenotypic characteristics from published cases.
  • Phenotypic analysis requiring frozen tissue, focusing on antigen expression (CD4, CD56, CD123).

Related Experiment Videos

  • Comparison with known cell lineages (B-cell, T-cell, NK-cell, myeloid-cell) and investigation of plasmacytoid dendritic cell homology.

    • Main Results:

    • The neoplasm primarily affects the skin and can develop a leukemic phase.
    • Diagnosis relies on phenotypic criteria, notably CD4 and CD56 expression, with other lineage markers negative.
    • Plasmacytoid dendritic cell origin is a strong candidate due to shared phenotypical and functional characteristics, including CD123 expression.
    • The median survival is poor, approximately 14 months, regardless of treatment.

    Conclusions:

    • Hematodermic CD4/CD56 neoplasm presents with skin tropism and a potential leukemic phase.
    • The tumor cells express CD4 and CD56, but their precise lineage remains unresolved, with plasmacytoid dendritic cells as a likely origin.
    • The disease has a very poor prognosis, with conventional therapies proving largely ineffective.